SOUTH
SAN FRANCISCO, Calif., July 5, 2024
/PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision
medicine oncology company committed to the discovery and
development of targeted therapeutics, today announced that the
company plans to issue a pre-market press release and conduct an
investor webcast on Monday, July 8, 2024, at 8:00 a.m. EST to provide a clinical data update
for the IDE397 Phase 2 monotherapy expansion dose in MTAP-deletion
urothelial and non-small cell lung cancer (NSCLC) patients. IDE397
is a potent and selective potential first-in-class methionine
adenosyltransferase 2 alpha (MAT2A) inhibitor in Phase 2 clinical
trials for the treatment of methylthioadenosine phosphorylase
(MTAP) deletion solid tumors.
The investor webcast presentation agenda to review the IDE397
clinical data update of the Phase 2 expansion dose results in
MTAP-deletion urothelial and NSCLC patients will be the
following:
- Market introduction: U.S. annual incidence in
MTAP-deletion solid tumors
- IDE397 preclinical summary in MTAP-deletion
- Patient baseline characteristics
- Pharmacokinetics and pharmacodynamics
- Adverse event profile
- Clinical efficacy in 18 evaluable MTAP-deletion urothelial
and NSCLC patients by RECIST 1.1
- Overall Response Rate (%ORR) and Disease Control Rate (%DCR)
analysis
- Swimlane plot
- ctDNA molecular response analysis
- Case reports and CT-scan images
The IDEAYA speakers will include Yujiro
S. Hata, Chief Executive Officer, Darrin Beaupre, M.D., Ph.D., Chief Medical
Officer, and Michael White, Ph.D.,
Chief Scientific Officer. The link to the investor webcast will be
available on the Investor Relations Events section of the
Company's website at: https://ir.ideayabio.com/events. Registration
is available at https://ir.ideayabio.com/events or
https://lifescievents.com/event/ideaya-2/ in advance of the
event.
IDEAYA's IDE397 investor webcast presentation, as well as an
updated corporate presentation, which will incorporate the updated
IDE397 clinical data, will be available on the company's website,
at its Investor Relations portal (https://ir.ideayabio.com/) at
approximately 8:00 am ET on Monday, July 8,
2024.
There is an ongoing Phase 2 expansion of IDE397 monotherapy in
MTAP-deletion solid tumors (NCT04794699), and an Amgen-sponsored
Phase 1/2 trial of IDE397 and Amgen's investigational
MTA-cooperative protein arginine methytranferase 5
inhibitor AMG 193 combination in MTAP-deletion NSCLC
(NCT05975073) for which the companies intend to develop a joint
publication strategy in 2024. In addition, IDEAYA has initiated
enrollment in a Phase 1 clinical trial evaluating the safety,
tolerability, pharmacokinetics, pharmacodynamics and efficacy of
IDE397 in combination with Gilead's Trop-2 directed anti-body
conjugate Trodelvy (NCT04794699). IDEAYA is also
advancing multiple preclinical stage MTAP-deletion programs to
enable wholly-owned combinations with IDE397, including a program
targeting a development candidate nomination in the second half of
2024.
About IDEAYA Biosciences
IDEAYA is a precision
medicine oncology company committed to the discovery and
development of targeted therapeutics for patient populations
selected using molecular diagnostics. IDEAYA's approach integrates
capabilities in identifying and validating translational biomarkers
with drug discovery to select patient populations most likely to
benefit from its targeted therapies. IDEAYA is applying its
research and drug discovery capabilities to synthetic lethality –
which represents an emerging class of precision medicine
targets.
Forward-Looking Statements
This press release contains
forward-looking statements, including, but not limited to,
statements related to (i) the timing and content of the IDE397
clinical data update press release, investor webcast and
investor presentations, (ii) the timing for the development of a
joint Amgen/IDEAYA publication strategy for the Phase 1/2 IDE397
and AMG 193 combination, (iii) the timing of preclinical stage
MTAP-deletion programs in combination with IDE397 and (iv)
nomination of an IDE397 combination development candidate in the
second half of 2024. IDEAYA undertakes no obligation to update or
revise any forward-looking statements. Such forward-looking
statements involve substantial risks and uncertainties. For a
further description of the risks and uncertainties that could cause
actual events and results to differ from those expressed in these
forward-looking statements, as well as risks relating to the
business of IDEAYA in general, see IDEAYA's Annual Report on Form
10-K filed on February 20, 2024,
Quarterly Report on Form 10-Q filed on May
7, 2024 and any additional current and periodic reports
filed with the U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-announces-investor-webcast-to-report-clinical-data-update-for-ide397-phase-2-monotherapy-expansion-dose-in-mtap-deletion-urothelial-and-lung-cancer-on-monday-july-8-2024-302190198.html
SOURCE IDEAYA Biosciences, Inc.
